Genentech's Xolair receives US FDA approval for allergic asthma treatment
Roche Group member Genentech has received the Food and Drug Administration (FDA) approval for Xolair (omalizumab) to treat children with moderate to severe persistent allergic asthma. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 10, 2016 Category: Pharmaceuticals Source Type: news
FDA Approves Genentech ’s Xolair (omalizumab) for Allergic Asthma in Children
South San Francisco, CA -- July 7, 2016 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) to treat moderate to severe persistent... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 7, 2016 Category: Drugs & Pharmacology Source Type: news
FDA Approves Genentech’s Xolair (omalizumab) for Allergic Asthma in Children
South San Francisco, CA -- July 7, 2016 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) to treat moderate to severe persistent... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 7, 2016 Category: Drugs & Pharmacology Source Type: news
Omalizumab cost effective for chronic urticaria in UK
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 31, 2016 Category: Drugs & Pharmacology Source Type: news
Roche reports solid sales growth in the first quarter of 2016
In the first quarter of 2016, Group sales rose 4% to CHF 12.4 billion. Sales in the Pharmaceuticals Division were up 4% to CHF 9.8 billion with Europe growing 5%, driven by Perjeta, MabThera and RoActemra. Pharmaceuticals sales in the US increased 3%, led by Esbriet, Xolair and HER2-positive breast cancer medicines. The recently launched medicines Cotellic in skin cancer and Alecensa in lung cancer have had a good start. (Source: World Pharma News)
Source: World Pharma News - April 19, 2016 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news
Omalizumab improves quality of life, angioedema in refractory urticaria patients
WASHINGTON – Treatment with omalizumab improved quality-of-life scores and had a significant impact on angioedema episodes in a phase IIIb study of people with treatment-refractory chronic idiopathic/spontaneous urticaria.
In the double-blind <a... (Source: Skin and Allergy News)
Source: Skin and Allergy News - March 15, 2016 Category: Dermatology Source Type: news
Omalizumab decreases colds in inner-city children with asthma
Treatment with omalizumab significantly decreases the number of colds in inner-city children with allergic asthma, researchers report. Omalizumab, sold under the brand name Xolair, is an injectable antibody that can be used to treat asthma cases not controlled by inhaled corticosteroids. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 7, 2016 Category: Science Source Type: news
Xolair May Reduce Rate of Cold Symptoms in Asthmatic Kids
(MedPage Today) -- Study assessed omalizumab paired with guideline-based treatment (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 7, 2016 Category: Allergy & Immunology Source Type: news
Omalizumab decreases colds in inner-city children with asthma, NIH study reports
(NIH/National Institute of Allergy and Infectious Diseases) Treatment with omalizumab significantly decreases the number of colds in inner-city children with allergic asthma, researchers reported at a press conference today at the American Academy of Allergy, Asthma and Immunology 2016 Annual Meeting in Los Angeles. Omalizumab, sold under the brand name Xolair, is an injectable antibody that can be used to treat asthma cases not controlled by inhaled corticosteroids. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 5, 2016 Category: Global & Universal Source Type: news
Better targeting of treatment gives hope to people with severe asthma
(NIHR Office for Clinical Research Infrastructure) A new study brings hope to severe allergic asthma patients by investigating whether the drug Omalizumab can be better targeted. The antibody treatment Omalizumab is an approved therapy for people who do not respond to steroid treatment and it is hoped that better targeting could save both lives and money in the NHS. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 1, 2016 Category: Global & Universal Source Type: news
JACI Publishes Results from Oral Immunotherapy Study with Omalizumab
First Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab in Patients with Severe Milk Allergy(PRWeb November 12, 2015)Read the full story at http://www.prweb.com/releases/2015/11/prweb13079239.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 13, 2015 Category: Pharmaceuticals Source Type: news
Published in JACI: New Asthma Treatment Strategy With Omalizumab...
Researchers’ introduce biologic treatments for asthmatics prone to exacerbations(PRWeb October 27, 2015)Read the full story at http://www.prweb.com/releases/2015/10/prweb13046602.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 27, 2015 Category: Pharmaceuticals Source Type: news
Your NEJM Group Today: Acute Colonic Pseudo-Obstruction Image, Omalizumab for Chronic Hives, Mass. Primary Care Opportunity (FREE)
By The Editors
NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - January 29, 2015 Category: Primary Care Source Type: news
Chronic Idiopathic Urticaria: Treatment With OmalizumabChronic Idiopathic Urticaria: Treatment With Omalizumab
Learn more about omalizumab, a fully humanized monoclonal antibody which shows promise as a new third-line option for chronic spontaneous urticaria, a common autoimmune skin condition. Skin Therapy Letter (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 27, 2015 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news
Pennsylvania Xarelto Lawsuits Consolidated With Creation of Mass Tort...
The Firm is representing plaintiffs in Xarelto lawsuits that allege the blood thinner places patients at risk for uncontrollable internal bleeding and other life-threatening complications.(PRWeb January 23, 2015)Read the full story at http://www.prweb.com/releases/xarelto-lawsuit/xolair-side-effects/prweb12467948.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 24, 2015 Category: Pharmaceuticals Source Type: news
